BC
KNSA icon

BIT Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

BIT Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Hold
5,138
– – 0.01% 93
2026
Q1 		$247K Sell
5,138
-7,662
-60% -$339K 0.01% 85
2025
Q4 		$528K Buy
+12,800
New +$513K 0.02% 90
2025
Q2 		– Sell
-11,878
Closed -$264K – 103
2025
Q1 		$264K Buy
+11,878
New +$244K 0.02% 96

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

BIT Capital's KNSA Position: Q2 2026 in Review

BIT Capital held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 5,138 shares worth $329K. The position accounts for 0.01% of the portfolio, ranked #93.

BIT Capital first reported a position in KNSA in Q1 2025 and has held it in 4 quarters since. The position peaked at $528K in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • BIT Capital held 5,138 shares of Kiniksa Pharmaceuticals worth $329K as of Q2 2026.
  • BIT Capital left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up 0.01% of BIT Capital's portfolio in Q2 2026, its #93 holding.
  • BIT Capital first reported a position in Kiniksa Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • BIT Capital's Kiniksa Pharmaceuticals position peaked at $528K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on BIT Capital's 13F filing for Q2 2026, filed 12 Aug 2026.